

MINUTES OF PROCEEDINGS

TUESDAY, November 1, 1966.

(22)

The Special Committee on Drug Costs and Prices met this day at 9.45 a.m. The Chairman, Mr. Harry C. Harley, presided.

Members present: Messrs. Brand, Goyer, Harley, Howe (*Hamilton South*), Isabelle, Johnston, Mackasey, MacLean (*Queens*), O'Keefe, Tardif (10).

In attendance: Representing Charles E. Frosst & Co.: Mr. James E. Frosst, President; Dr. R. S. Stuart, Director of Research; Mr. A. F. Coffin, Vice President—Sales; Dr. J. R. Ibberson, Executive Medical Director; Mr. J. M. Blanch, Vice President—Finance, all of Montreal.

Also in attendance: Mr. A. M. Laidlaw, Q.C. of Ottawa, Legal Counsel for the Committee.

The Chairman read into the record a letter from Mr. Lawrence Wilson of Montreal, who appeared before the Committee on October 13, to correct an impression that might be gathered from the evidence given on page 571, with reference to the drug MER-29.

The Committee proceeded to the consideration of the submission made by Charles E. Frosst & Co.

The Chairman introduced Mr. James E. Frosst who introduced the members of his company and read a prepared statement.

Mr. Frosst was examined on the brief. He was assisted by Dr. Stuart, Mr. Coffin, Dr. Ibberson and Mr. Blanch.

With reference to a question asked by Mr. Howe (*Hamilton South*), about different selling prices of drugs being exported to other countries, this information being unavailable, Mr. Frosst agreed to supply it in writing in the near future.

Agreed,—That the submission by Charles E. Frosst & Co. be printed as an appendix to this day's proceedings. (*See Appendix "A"*)

Mr. Frosst was further examined.

Mr. Laidlaw also asked questions, more specifically, on patents.

The Chairman thanked Charles E. Frosst & Co. for their submission and the officials of the Company for the information supplied to the Members.

At 11.55 a.m. the Committee adjourned to 9.30 a.m. Thursday, November 3.

Gabrielle Savard,
Clerk of the Committee.